The present invention relates to methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions. ##STR00001##

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

The subject invention pertains to methods to produce amorphous materials at nanometer scale, by solidifying or hardening the materials inside nanometer-sized pores of porous media (i.e., porous templates). The porous templates can be made by packing nanometer-sized particles or other means. The subject invention further pertains to methods to produce the porous templates used to produce amorphous material at nanometer scale.

An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and a mouth-soluble binder dispersed in the mouth-stable polymer matrix.

A method of forming a chemical delivery device with an active chemical includes generating halftoned image data using a stochastic halftone screen and with reference to a concentration parameter for the active chemical. The method also includes ejecting a chemical carrier including the active chemical into a portion of a plurality of cavities formed in the chemical delivery device based on the halftoned image data to produce the chemical delivery device with a concentration of the active chemical corresponding to the concentration parameter.

The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein.

The present invention discloses solid oromucosal pharmaceutical formulations containing a psychedelic selected from psilocybin, psilocin, or mescaline and/or an analog thereof as an active ingredient, a method of preparation of the pharmaceutical form by Selective Laser Sintering (SLS) 3D printing, and treatment of neurological and/or psychiatric disorders, as well as inflammatory disorders.

Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.